Continuous Bioprocessing Market is Expected to Reach $599 million | MarketsandMarkets.
Chicago, Dec. 05, 2023 (GLOBE NEWSWIRE) -- *Continuous Bioprocessing market* in terms of revenue was estimated to be worth $218 million in 2023 and is poised to reach $599 million by 2028, growing at a CAGR of 22.4% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. The growth of this market is majorly driven by rising focus on rising demand for biopharmaceuticals, growing adoption among CDMOs and CMOs, advantages of continuous bioprocessing over batch/fed-batch mode, among others. The growing demand for biopharmaceuticals is a key growth driver of the continuous bioprocessing market. Biopharmaceuticals, including monoclonal antibodies, vaccines, and gene therapies, have gained significant prominence due to their efficacy and potential in treating a wide range of diseases such as cancer, autoimmune diseases, and infectious diseases. Meeting the surging demand for biopharmaceuticals has been challenging due to the complex and resource-intensive manufacturing processes involved. Continuous bioprocessing allows for a streamlined and uninterrupted production workflow, eliminating the need for traditional batch-based processing and saving time.
*Download an Illustrative overview:* *https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=75067818*
*Continuous Bioprocessing** Market** Scope:*
*Report Coverage* *Details*
Market Revenue in 2023 $218 million
Estimated Value by 2028 $599 million
Growth Rate Poised to grow at a CAGR of 22.4%
Market Size Available for 2021–2028
Forecast Period 2023–2028
Forecast Units Value (USD Million)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Product, Scale of Operation, Process, Application & End User
Geographies Covered North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
Report Highlights Updated financial information / product portfolio of players
Key Market Opportunity PAT-enabled optimization of continuous bioprocesses
Key Market Driver The emergence of integrated end-to-end continuous bioprocessing is projecting the market growth
Based on product, the continuous bioprocessing market is segmented into chromatography systems & consumables; filtration systems & devices; bioreactors; cell culture media, cell lines, buffers, and reagents; and other products. In 2022, the chromatography systems and consumables segment accounted for the largest share of the continuous bioprocessing market. The key factors contributing to market growth include the rising demand for biologics, the growing need for intensification of the downstream process due to increased titer through perfusion technology, the availability of off-the-shelf chromatography products for continuous operations, and the successful implementation of continuous downstream processes in several studies.
Based on process, the continuous bioprocessing market is segmented into upstream & downstream bioprocesses. In 2022, the downstream bioprocess segment accounted for the largest share of the continuous bioprocessing market. This segment is also expected to grow at the highest CAGR during the forecast period. The large share and high growth rate of the segment can be attributed to large share and high growth rate of the downstream process segment can be attributed to the growing focus on reducing production costs for biosimilars and innovator drugs; rising technological advancements such as SPTFF and multicolumn chromatography; the rising need for intensification of the downstream process due to increased titer; and the growing demand for biopharmaceuticals.
Based on end user, the continuous bioprocessing market is segmented into pharmaceutical & biotechnology companies, contract research organizations and contract manufacturing organizations (CROs & CMOs), and academic & research institutes. In 2022, the pharmaceutical & biotechnology companies segment accounted for the largest share of the continuous bioprocessing market. The rising demand for biopharmaceuticals and development of biosimilars for the treatment of chronic diseases is expected to be a key growth driver for this end-user segment. This has resulted in the growing focus of biopharmaceutical companies on the development of affordable biologics at lower costs. The adoption of single-continuous bioprocessing equipment is gradually increasing due to its wide applications in research & process development and the increasing manufacturing of biologics and biosimilars.
The key regional markets for the global continuous bioprocessing market are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the market. This can be attributed to the the presence of a well-established biopharmaceutical industry major players operating in the continuous bioprocessing market, and growing biologics and biosimilars market. Asia Pacific market is estimated to grow at the highest CAGR during the forecast period owing to the continuous growth of the biopharmaceutical industry, growth in life sciences research activities, rising investments by pharmaceutical & biotechnology companies, and the growing CRO & CMO market.
*Buy a Continuous Bioprocessing Industry Report (273 Pages PDF with Insightful Charts, Tables, and Figures): **https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=75067818*
*Continuous Bioprocessing market major players covered in the report, such as:*
· Danaher Corporation (US)
· Sartorius AG (Germany)
· Thermo Fisher Scientific Inc. (US)
· Repligen Corporation (US)
· Merck KGaA (Germany)
· 3M Company (US)
· Getinge AB (Sweden)
· Eppendorf SE (Germany)
· Corning Incorporated (US)
· Entegris (US)
· FUJIFILM Holdings Corporation (Japan)
· Meissner filtration products Inc. (US)
· Kühner AG (Switzerland)
· Esco Lifesciences Group (Singapore)
· SATAKE MultiMix Corporation (Japan)
· Bionet (Spain)
· Stobbe Group (Switzerland)
· bbi-biotech GmbH (Germany)
· OmniBRx Biotechnologies (India)
· Cell Culture Company LLC (US)
· Pierre Guérin (France)
· Solida Biotech GmbH (Germany)
· Zellwerk GmbH (Germany)
· 3D Biotek LLC (US)
· FiberCell Systems Inc. (US)
· and Among Others
*Request for FREE Sample Pages: **https://www.marketsandmarkets.com/requestsampleNew.asp?id=75067818*
*This report categorizes the continuous bioprocessing market into the following segments:*
*Continuous Bioprocessing Market, by Product*
· Chromatography Systems and Consumables
· Filtration Systems and Devices
· Bioreactors
· Cell Culture Media, Cell Lines, Buffers and Reagents
· Other Products*Continuous Bioprocessing Market, by Scale of Operation*
· Commercial Operations
· Clinical Operations
*Continuous Bioprocessing Market, by Process*
· Downstream Bioprocess
· Upstream Bioprocess
*Continuous Bioprocessing Market, by Application*
· Monoclonal Antibodies
· Vaccines
· Cell and Gene Therapy
· Other Applications
*Continuous Bioprocessing Market, by End User*
· Pharmaceutical and Biotechnology Companies
· Contract Research Organizations and Contract Manufacturing Organizations
· Academic and Research Institutes
*Continuous Bioprocessing Market, by region*
· North America
· US
· Canada
· Europe
· Germany
· UK
· France
· Italy
· Spain
· Rest of Europe (RoE)
· Asia Pacific (APAC)
· China
· Japan
· India
· South Korea
· Rest of Asia Pacific (RoAPAC)
· Latin America
· Brazil
· Mexico
· RoLATAM
· Middle East & Africa
· Middle East
· Africa
*Get 10% Free Customization on this Report: **https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=75067818*
*Recent Developments:*
· In August 2023, Sartorius collaborated with Repligen Corporation and launched the Integrated bioreactor system. This system incorporates Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor to simplify intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.
· In July 2022, Cytiva expanded its operations with a new facility in Muskegon, Michigan. The new chromatography resins manufacturing site is part of Cytiva’s expansion investment.
*Key Stakeholders:*
· Continuous bioprocessing product manufacturers and distributors
· Pharmaceutical and biotechnology companies
· Healthcare service providers (including hospitals and clinics)
· R&D companies
· Academic institutes
· Government associations
· Market research and consulting firms
· Venture capitalists and investors
*Report Objectives:*
· To define, describe, and forecast the global continuous bioprocessing market based on the product, scale of operation, process, application, end user and region
· To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities and challenges)
· To strategically analyze micro-markets with respect to individual growth trends, future prospects, and contributions to the overall continuous bioprocessing market
· To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
· To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
· To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
· To track and analyze competitive developments such as acquisitions, product launches, expansions, and R&D activities in the continuous bioprocessing market.
*Related Reports:*
*Peptide Synthesis Market*
*Proteomics Market*
*Life Science Instrumentation Market*
*Glycomics Market*
*Therapeutic Drug Monitoring Market*
*Research Insight:* https://www.marketsandmarkets.com/ResearchInsight/continuous-bioprocessing-market.asp
*Content Source: *https://www.marketsandmarkets.com/PressReleases/continuous-bioprocessing.asp
CONTACT: About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com